OTCMKTS:RGBP Regen BioPharma (RGBP) Stock Price, News & Analysis $0.05 -0.01 (-9.09%) As of 03/28/2025 09:54 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsSEC FilingsShort InterestBuy This Stock About Regen BioPharma Stock (OTCMKTS:RGBP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Regen BioPharma alerts:Sign Up Key Stats Today's Range$0.05▼$0.0650-Day Range$0.04▼$0.0952-Week Range$0.02▼$0.60Volume1,160 shsAverage Volume14,991 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRegen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is involved in the development of its products, and therapies, including HemaXellarate, a cellular therapeutic product of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6. The company was incorporated in 2012 and is based in La Mesa, California.Read More… Remove Ads Receive RGBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regen BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address RGBP Stock News HeadlinesRegen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerateNovember 28, 2024 | finanznachrichten.deRegen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate(TM)November 21, 2024 | stockhouse.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.March 29, 2025 | Paradigm Press (Ad)Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™November 19, 2024 | globenewswire.comRegen BioPharma, Inc. to Present at the Emerging Growth Conference on September 25, 2024, At 4 pm Eastern TimeSeptember 23, 2024 | globenewswire.comRegeneron Pharmaceuticals, Inc. (REGN): The Best Biotech Stock According to Hedge Funds?September 8, 2024 | msn.comRegen BioPharma Inc (RGBP)August 31, 2024 | investing.comRegen BioPharma, Inc. to Present at the Emerging Growth Conference on May 9, 2024May 7, 2024 | finance.yahoo.comSee More Headlines RGBP Stock Analysis - Frequently Asked Questions How have RGBP shares performed this year? Regen BioPharma's stock was trading at $0.0601 at the beginning of 2025. Since then, RGBP stock has decreased by 16.8% and is now trading at $0.05. View the best growth stocks for 2025 here. When did Regen BioPharma's stock split? Regen BioPharma's stock split before market open on Thursday, June 20th 2024. The 3-1 split was announced on Thursday, June 20th 2024. The newly issued shares were distributed to shareholders after the closing bell on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. How do I buy shares of Regen BioPharma? Shares of RGBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Regen BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regen BioPharma investors own include Meta Platforms (META), Trans Global Group (TGGI), Exxe Group (AXXA), DraftKings (DKNG), Enzolytics (ENZC), Alcoa (AA) and Airborne Wireless Network (ABWN). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:RGBP CIK1589150 Webwww.regenbiopharmainc.com Phone(619) 722-5505FaxN/AEmployees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (OTCMKTS:RGBP) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regen BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regen BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.